Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price dropped 1.6% during mid-day trading on Thursday . The stock traded as low as C$8.01 and last traded at C$8.01. Approximately 1,419 shares traded hands during trading, an increase of 17% from the average daily volume of 1,212 shares. The stock had previously closed at C$8.14.
Devonian Health Group Trading Down 1.6%
The company has a 50 day moving average of C$10.67 and a 200 day moving average of C$11.40. The firm has a market cap of C$22.28 million, a P/E ratio of -2.31 and a beta of 0.46. The company has a debt-to-equity ratio of 16.36, a quick ratio of 7.82 and a current ratio of 1.07.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Read More
- Five stocks we like better than Devonian Health Group
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
